CD96 and bladder transitional cell carcinoma: On the contrary, increased CD96 expression was associated with the better prognosis in BLCA (HR = 0.96, 95% CI = 0.93–0.98, P = 4.3e-4), CESC (HR = 0.94, 95% CI = 0.89–0.99, P = 0.025), HNSC (HR = 0.95, 95% CI = 0.91–0.98, P = 0.005), SKCM (HR = 0.96, 95% CI = 0.94–0.98, P = 9.3e-4), and thymoma (THYM) (HR = 0.95, 95% CI = 0.92–0.99, P = 0.021).